Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC
Advanced Hepatocellular Carcinoma
DRUG: SHR-8068|DRUG: Adebrelimab|DRUG: Bevacizumab|DRUG: Sintilimab
Progression Free Survival (PFS), From Randomization to the first occurrence of disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 or initiation of new anti-tumor therapy (up to approximately 36 months)|Overall survival (OS), OS is defined as the time from randomization to death from any cause, From randomization to death from any cause (whichever occurs first) (up to approximately 36 months)
Time to Progression (TTP), TTP is defined as the time from randomization to the until first evidence of disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1, From randomization to the first occurrence of disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 (up to approximately 36 months)]|Disease Control Rate (DCR), DCR is defined as the proportion of participants with Complete Response (CR), Partial Response (PR) or Stable Disease (SD), as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1, From Randomization to the first occurrence of disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 or initiation of new anti-tumor therapy (up to approximately 36 months)|Objective Response Rate (ORR), ORR is defined as the proportion of participants with Complete Response (CR) or Partial Response (PR), as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1, From Randomization to the first occurrence of disease progression or initiation of new anti-tumor therapy (up to approximately 36 months)|Duration of Response (DoR), DOR is defined as the time from the first occurrence of a confirmed objective response to disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 or death from any cause (whichever occurs first), From the first occurrence of a confirmed objective response to disease progression as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 or death from any cause (whichever occurs first) (up to approximately 36 months)|Time to Response (TTR), TTR is defined as time from the randomization of Complete Response (CR) or Partial Response (PR) by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1, From the first occurrence of complete response (CR) or partial response (PR) as determined by the Blinded Independ Review Committee (BIRC) according to RECIST v1.1 (up to approximately 36 months)|The incidence, severity and relevance to investigational drugs of adverse events (AE) and serious adverse events (SAE) according to NCI-CTCAE v5.0, From the ICF date until the end of the safety follow-up or initiation of new anti-tumor therapy (up to approximately 36 months)
To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC